• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEO

    NeoGenomics Inc.

    Subscribe to $NEO
    $NEO
    Precision Instruments
    Health Care

    NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

    IPO Year:

    Exchange: NASDAQ

    Website: neogenomics.com

    Recent Analyst Ratings for NeoGenomics Inc.

    DatePrice TargetRatingAnalyst
    4/30/2025$9.00Outperform → Market Perform
    Leerink Partners
    1/13/2025Buy → Hold
    The Benchmark Company
    12/10/2024$22.00Buy
    Jefferies
    5/1/2024$26.00Buy
    Craig Hallum
    12/29/2023$25.00 → $21.00Buy
    BTIG Research
    8/21/2023$18.00Equal-Weight → Overweight
    Stephens
    5/16/2023Outperform → Mkt Perform
    Raymond James
    5/9/2023$25.00Neutral → Buy
    BTIG Research
    2/24/2023$20.00Hold → Buy
    The Benchmark Company
    2/1/2023$15.00Hold → Buy
    Needham
    See more ratings

    NeoGenomics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by NeoGenomics Inc.

      10-Q - NEOGENOMICS INC (0001077183) (Filer)

      4/29/25 4:06:41 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      4/29/25 7:35:33 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form DEFA14A filed by NeoGenomics Inc.

      DEFA14A - NEOGENOMICS INC (0001077183) (Filer)

      4/23/25 4:01:58 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form DEF 14A filed by NeoGenomics Inc.

      DEF 14A - NEOGENOMICS INC (0001077183) (Filer)

      4/8/25 4:11:02 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      4/8/25 4:07:04 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Amendment: NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K/A - NEOGENOMICS INC (0001077183) (Filer)

      3/31/25 4:07:18 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Amendment: NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K/A - NEOGENOMICS INC (0001077183) (Filer)

      3/19/25 4:10:12 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      3/18/25 5:30:48 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form 10-K filed by NeoGenomics Inc.

      10-K - NEOGENOMICS INC (0001077183) (Filer)

      2/18/25 4:16:39 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEOGENOMICS INC (0001077183) (Filer)

      2/18/25 7:08:18 AM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tetrault Lynn A. bought $56,974 worth of shares (7,000 units at $8.14) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:26:57 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Kanovsky Stephen M bought $31,124 worth of shares (4,000 units at $7.78), increasing direct ownership by 11% to 40,090 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:24:53 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Executive Officer Zook Anthony P. bought $148,919 worth of shares (18,900 units at $7.88) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/8/25 4:13:18 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Perez David Brian bought $76,300 worth of shares (10,000 units at $7.63) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/7/25 4:05:54 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Gunn Neil bought $34,977 worth of shares (4,510 units at $7.75), increasing direct ownership by 40% to 15,846 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/7/25 4:05:23 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Financial Officer Sherman Jeffrey Scott bought $150,104 worth of shares (20,000 units at $7.51), increasing direct ownership by 14% to 158,494 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/6/25 4:08:57 PM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tetrault Lynn A. bought $56,974 worth of shares (7,000 units at $8.14) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:26:57 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Kanovsky Stephen M bought $31,124 worth of shares (4,000 units at $7.78), increasing direct ownership by 11% to 40,090 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/9/25 5:24:53 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Executive Officer Zook Anthony P. bought $148,919 worth of shares (18,900 units at $7.88) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/8/25 4:13:18 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Perez David Brian bought $76,300 worth of shares (10,000 units at $7.63) (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/7/25 4:05:54 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Director Gunn Neil bought $34,977 worth of shares (4,510 units at $7.75), increasing direct ownership by 40% to 15,846 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/7/25 4:05:23 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Financial Officer Sherman Jeffrey Scott bought $150,104 worth of shares (20,000 units at $7.51), increasing direct ownership by 14% to 158,494 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/6/25 4:08:57 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Pres & Chief Operating Officer Stone Warren converted options into 5,969 shares and covered exercise/tax liability with 1,454 shares, increasing direct ownership by 5% to 95,308 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/6/25 4:07:03 PM ET
      $NEO
      Precision Instruments
      Health Care
    • Chief Accounting Officer Aunan Greg D covered exercise/tax liability with 2,246 shares and converted options into 5,372 shares, increasing direct ownership by 22% to 17,579 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/5/25 4:06:13 PM ET
      $NEO
      Precision Instruments
      Health Care
    • EVP, GC & Business Development Olivo Alicia C covered exercise/tax liability with 652 shares, decreasing direct ownership by 1% to 44,701 units (SEC Form 4)

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      5/5/25 4:05:27 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Pres & Chief Operating Officer Stone Warren

      4 - NEOGENOMICS INC (0001077183) (Issuer)

      4/3/25 4:07:33 PM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NeoGenomics Pays Off 1.25% Convertible Senior Notes

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predict

      5/1/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

      FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary ultra-high throughput next-generation sequencing (NGS) platform, today announced a collaboration to use Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance NeoGenomics' ability to offer innovative clinical tests. NeoGenomics has purchased a UG 100 sequencer that will be installed in its innovation center in Cambridge, UK.

      4/29/25 8:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Reports First Quarter 2025 Results

      Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

      4/29/25 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

      Additional Presentations Demonstrate Ongoing Commitment to Research & Innovation in Precision Oncology NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling. The validation study, along with five additional abstracts, will be presented at the American Association for Cancer Research® (AACR) Annual Meeting 2025 in Chicago, April 25–30. PanTracer LBx is a blood-based test that analyzes circulating tumor DNA to identify key genomic alterations in patients w

      4/22/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o

      4/8/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Completes Acquisition of Pathline

      Patients and physicians will benefit from access to NeoGenomics' broad test menu and high-quality laboratory services in the Tri-state area NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing. About

      4/7/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company's Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in healthcare. "Tony has a strong command of the healthcare landscape and a deep understanding of the opportunities ahead for NeoGenomics," said Lynn Tetrault, Chair of the Board. "His experience leading commercial and operational teams, combined with his significant connection to our strategy, make him the

      4/1/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

      Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

      3/18/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev

      3/10/25 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Participate in Upcoming Investor Conferences

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here Leerink Partners Global Healthcare Conference in Miami, FL Fireside chat on Tuesday, March 11 at 3:30 p.m. ET, accessible here Barclays 27th Annual Global Healthcare Conference in Miami, FL Fireside chat on Thursday, March 13 at 9:00 a.m. ET, accessible here Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company's websi

      2/24/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Financials

    Live finance-specific insights

    See more
    • NeoGenomics Reports First Quarter 2025 Results

      Consolidated Revenue Increased 8% to $168 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025. First Quarter 2025 Highlights As Compared To First Quarter 2024 Consolidated revenue increased 8% to $168 million Net loss decreased 4% to $26 million Adjusted EBITDA increased 102% to positive $7 million "Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year," said Ton

      4/29/25 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) o

      4/8/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

      NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics' commercial presence in the Northeast U.S., expanding its service capabilities and accelerating growth in molecular and hematology-oncology testing by establishing a local presence for the company in a historically under penetrated but rapidly growing geographical region of the country. Founded in 2009, Pathline serves a long-standing client base of hospitals, cancer centers, and physician practices, with approximately 98% of its rev

      3/10/25 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

      Full Year Revenue Increased 12% to $661 million; Ninth Consecutive Quarter of Double-Digit Revenue Growth NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter consolidated revenue increased 11% to $172 million; Full year consolidated revenue increased 12% to $661 million Fourth quarter net loss increased 7% to $15 million; Full year net loss decreased 11% to $79 million Fourth quarter adjusted EBITDA increased 27% to positive $12 million; Full year adjusted EBITDA increased 1,036% to

      2/18/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

      NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (i

      1/29/25 8:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Reports Third Quarter 2024 Results

      Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023   Consolidated revenue increased 10% to $168 million Clinical Services revenue increased 14% to $146 million Advanced Diagnostics revenue decreased 10% to $22 million Net loss decreased 4% to $18 million Adjusted EBITDA increased 305% to positive $13 million "We delivered a strong third quarter, again gro

      11/5/24 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

      NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior

      10/15/24 7:30:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation

      Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t

      9/23/24 6:47:00 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Reports Second Quarter 2024 Results

      Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023   Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart

      7/29/24 4:05:00 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024

      NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior

      7/9/24 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NeoGenomics Inc.

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      11/14/24 1:28:29 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/14/24 10:04:34 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/13/24 5:09:41 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/9/24 3:17:09 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/10/23 8:58:59 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/9/23 3:42:38 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/9/23 11:27:43 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G/A filed by NeoGenomics Inc. (Amendment)

      SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)

      2/6/23 2:56:55 PM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/4/22 9:21:27 AM ET
      $NEO
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by NeoGenomics Inc.

      SC 13G - NEOGENOMICS INC (0001077183) (Subject)

      2/4/22 6:17:28 AM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

      Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company's current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025. Mr. Stone has over 25 years of general management and cross-functional commercial experience. In his expanded role, he will be responsible f

      3/18/25 7:05:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • PacBio Announces Appointment of Chris Smith to Board of Directors

      MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

      1/30/25 9:05:00 AM ET
      $NEO
      $PACB
      Precision Instruments
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Felicia Williams Joins NeoGenomics Board of Directors

      NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa

      11/14/24 8:10:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

      PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

      6/10/24 1:00:00 AM ET
      $FLGT
      $NEO
      Medical Specialities
      Health Care
      Precision Instruments
    • NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

      FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was

      6/29/23 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors

      FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez - a veteran leader in medical devices and health care services - to serve on its Board of Directors, effective November 3, 2022."I am thrilled to welcome David to our Board of Directors. With his proven record in growing and scaling highly-regulated companies, David brings valuable experience and insights to NeoGenomics as the company continues to expand its testing and information services to transform cancer care," said Lynn Tetrault, Chair of the Board of NeoGenomics.With 40 years of global executive lead

      11/7/22 4:35:00 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Appoints Lynn Tetrault Interim CEO

      FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022.Ms. Tetrault has been serving as Executive Chair since March when the Company's CEO agreed to step down. Ms. Tetrault was overseeing the Interim Office of the CEO to provide seamless leadership continuity and operational management of the Company while the Board conducts a search for the Company's permanent CEO."Lynn's leadershi

      5/16/22 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary

      FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period.Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis l

      5/9/22 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics Announces CEO Departure and Initiates CEO Search

      Board Appoints Executive Chair and Interim Office of the CEOAnticipates First Quarter Results Below Guidance and Withdraws 2022 GuidanceFT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that the Board of Directors (the "Board") and Mark Mallon, Chief Executive Officer, have agreed that Mr. Mallon will step down as CEO and member of the Board, effective immediately. This mutual agreement was not the result of any disagreements about strategy with management or the Board, inappropriate action by CEO, or any violation of compan

      3/28/22 4:05:00 PM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

      FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th.Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. He also served as a tenured professor and Vice Chairman for Research in the number one Genetics Department in the US, Department of Molecular and

      2/14/22 7:00:00 AM ET
      $NEO
      Precision Instruments
      Health Care

    NeoGenomics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NeoGenomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded NeoGenomics from Outperform to Market Perform and set a new price target of $9.00

      4/30/25 8:08:08 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics downgraded by The Benchmark Company

      The Benchmark Company downgraded NeoGenomics from Buy to Hold

      1/13/25 8:42:07 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Jefferies initiated coverage on NeoGenomics with a new price target

      Jefferies initiated coverage of NeoGenomics with a rating of Buy and set a new price target of $22.00

      12/10/24 9:06:00 AM ET
      $NEO
      Precision Instruments
      Health Care
    • Craig Hallum resumed coverage on NeoGenomics with a new price target

      Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00

      5/1/24 9:17:47 AM ET
      $NEO
      Precision Instruments
      Health Care
    • BTIG Research reiterated coverage on NeoGenomics with a new price target

      BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously

      12/29/23 7:28:53 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics upgraded by Stephens with a new price target

      Stephens upgraded NeoGenomics from Equal-Weight to Overweight and set a new price target of $18.00

      8/21/23 9:11:26 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics downgraded by Raymond James

      Raymond James downgraded NeoGenomics from Outperform to Mkt Perform

      5/16/23 7:29:33 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics upgraded by BTIG Research with a new price target

      BTIG Research upgraded NeoGenomics from Neutral to Buy and set a new price target of $25.00

      5/9/23 6:42:47 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded NeoGenomics from Hold to Buy and set a new price target of $20.00

      2/24/23 7:21:13 AM ET
      $NEO
      Precision Instruments
      Health Care
    • NeoGenomics upgraded by Needham with a new price target

      Needham upgraded NeoGenomics from Hold to Buy and set a new price target of $15.00

      2/1/23 6:19:18 AM ET
      $NEO
      Precision Instruments
      Health Care